News

21 Jul 2017

Press – Newguard: Safer prefilled syringes & fewer changes

Given the rising number of guidelines to reduce risks of needlestick injuries, pharmaceutical companies have been searching for systems to ensure safe syringe use. Despite great innovations, adopting new safety systems has always been a trade-off between safety and the cost of implementing new processes. Now, Biocorp can offer Newguard™, a new passive safety system […]

Given the rising number of guidelines to reduce risks of needlestick injuries, pharmaceutical companies have been searching for systems to ensure safe syringe use. Despite great innovations, adopting new safety systems has always been a trade-off between safety and the cost of implementing new processes. Now, Biocorp can offer Newguard™, a new passive safety system integrated on prefilled syringes without such compromises being required.

Jean Vuillecard, Product Innovation Manager, Philippe Lesaulnier, Business Development Manger, and Eric Dessertenne, Head of Business Development, of Biocorp, explain more:

odd-pfs-newguard-syringe

Read this article

(ONdrugDelivery Magazine, issue 73, “Prefilled syringes”, on February 2017)

07 Jul 2017

Award – Inspair, winner at the eHealth Summer University

Inspair innovation – a smart sensor for inhalers – has been awarded at the international eHealth Summer University 2017 We are proud to announce that Inspair won the award of the best connected device innovation at the eHealth University on the 5th of July. Inspair is a healthcare solution for respiratory chronic conditions – like asthma and […]

Inspair innovation – a smart sensor for inhalers – has been awarded at the international eHealth Summer University 2017

We are proud to announce that Inspair won the award of the best connected device innovation at the eHealth University on the 5th of July.

Inspair is a healthcare solution for respiratory chronic conditions – like asthma and COPD – enhancing treatment compliance to inhaled therapies while supporting patients to improve their inhalation technique.

inspair-award

The eHealth University promotes international innovations that reshape healthcare. Among 8 eHealth categories, Inspair has been awarded as the best connected medical device innovation.

28 Jun 2017

Press – Interview on Biocorp’s connected medical devices

In this interview, Mr Guillet discusses Biocorp’s existing connected device offering, how it delivers value for the company’s pharmaceutical partners, the development of the accompanying software and data architecture, and how Biocorp has very significant opportunities to leverage its triple expertise in medical devices, electronics and software further. Read this article (ONdrugDelivery Magazine, issue 76, […]

In this interview, Mr Guillet discusses Biocorp’s existing connected device offering, how it delivers value for the company’s pharmaceutical partners, the development of the accompanying software and data architecture, and how Biocorp has very significant opportunities to leverage its triple expertise in medical devices, electronics and software further.

Connecting drug delivery

Read this article

(ONdrugDelivery Magazine, issue 76, “Connecting Drug Delivery”, on June 2017)

08 Jun 2017

Partnership – BIOCORP signs an industrialization contract with Virbac

BIOCORP signs an industrialization contract with Virbac for the manufacturing of an innovative administration and closure system compatible with vials.   BIOCORP  announces today the signature of an industrialization contract with Virbac, the 7 th veterinary company worldwide. BIOCORP, whose expertise and know-how are well-renowned, is thereby closing a deal in line with its strategy […]

BIOCORP signs an industrialization contract with Virbac for the manufacturing of an innovative administration and closure system compatible with vials.

 

BIOCORP  announces today the signature of an industrialization contract with Virbac, the 7 th veterinary company worldwide. BIOCORP, whose expertise and know-how are well-renowned, is thereby closing a deal in line with its strategy of creating new opportunities and manufacturing programs through specific developments implemented since 2015 (project-based services using BIOCORP’s expertise). Virbac Group, a company dedicated to animal health, employs over 4,800 people and has a global presence with subsidiaries in 31 countries, production centers in 11 countries and R&D centers on 5 continents. The investment deal was closed after a 24-month collaboration between BIOCORP and Virbac for the development of a delivery device adapted to the needs of the veterinary laboratory.

This device, an innovative administration and closure system for vials, is reusable and offers an optimal administration for products selected by Virbac. The first deliveries are expected between the 1st and 2nd quarter of 2018. BIOCORP will then be responsible for the production of the industrialized product.

“We are thrilled to announce the signature of this industrialization contract with Virbac which successfully concludes the R&D program custom-developed by our teams. This collaboration with Virbac, an expert in animal health, highlights the width of our scope and the wide range of applications of our expertise”, commented Jacques Gardette and Eric Dessertenne, respectively founder and CEO, and Chief Operating Officer of BIOCORP.

Read the Press release

05 Apr 2017

EVENT – European Smallcap Event – Paris – April 18&19

Biocorp’s CEO, Jacques Gardette and COO, Eric Dessertenne, will be attending the 12th edition of the European Smallcap. This event will take place in Paris on April 18 & 19, 2017.

Biocorp’s CEO, Jacques Gardette and COO, Eric Dessertenne, will be attending the 12th edition of the European Smallcap.
This event will take place in Paris on April 18 & 19, 2017.

07 Mar 2017

AWARD – Inspair, finalist for the AXA Health Tech & You Award

The Awards programme discovers, promotes and supports cutting-edge health technology innovations around the world. Now in its third year, the AXA PPP Health Tech & You Awards is an initiative led by AXA PPP healthcare that has established and promoted widespread awareness of the rapid rise of health tech and continues to empower people everywhere […]

The Awards programme discovers, promotes and supports cutting-edge health technology innovations around the world.

Now in its third year, the AXA PPP Health Tech & You Awards is an initiative led by AXA PPP healthcare that has established and promoted widespread awareness of the rapid rise of health tech and continues to empower people everywhere to use technology to live life well today and in the future and be more in control of their health and wellbeing.

Inspair solution has been shortlisted for the Wow category of the AXA Health Tech & You Award gathering the truly standout and disruptive innovations that will have everyone talking !

The Inspair solution will be exhibited at the Design Museum – in London – from Wednesday 26th April 2017 to Monday 8th May 2017.

 

25 Jan 2017

EVENT – Pharmapack 2017 on 1st-2nd February 2017 in Paris

BIOCORP to present its innovations at 20th Pharmapack exhibition BIOCORP, today announces it will be part of the 20th edition of Pharmapack exhibition, which will take place on 1st-2nd February 2017, in Paris (France). Pharmapack exhibition, which will take place at Paris Expo (France), has become one of the key meeting places for the pharmaceutical […]

BIOCORP to present its innovations at 20th Pharmapack exhibition
BIOCORP, today announces it will be part of the 20th edition of Pharmapack exhibition, which will take place on 1st-2nd February 2017, in Paris (France).
Pharmapack exhibition, which will take place at Paris Expo (France), has become one of the key meeting places for the pharmaceutical packaging and drug delivery industry players from all over the world1.
BIOCORP will participate at booth H8 and will present its innovations in pharmaceutical and connected medical devices. The company has already won two Best Exhibitor Innovation awards in 2015 and 2016 for its connected devices Datapen and Easylog. This year, BIOCORP will present its NewGuard in the Innovation Gallery, a new generation of integrated passive safety device compatible with various sizes of stacked needles PFS, under industrialization since the first half of 2016.
During Pharmapack exhibition, Eric Dessertenne, BIOCORP’s Chief Operating Officer, will also participate in two presentations as a speaker:
– Conference: “Go beyond tracking: guarantee better and safer treatment administration”, on February 1st, from 2:40PM to 3:05PM.
– Roundtable: “Market access, pricing and reimbursement strategies for innovative drug delivery and connected health products” (moderated by Faraj Abdelnour, President of ACIDIM), on February 2nd , from 2:50PM to 4:00PM.

Read the press release

05 Jan 2017

EVENT – Investor events January 2017

BIOCORP will participating in the upcoming events outlined below: J.P. Morgan 35th Annual Healthcare Conference, January 9 to 12, 2017 – San Francisco (CA, USA). Invest Securities Biomed Event, held on January 26, 2017 – Salons Hoche, Paris (France). Please contact BIOCORP at investisseurs@biocorp.fr to arrange a meeting at any of these events. see the […]

BIOCORP will participating in the upcoming events outlined below:

  • J.P. Morgan 35th Annual Healthcare Conference, January 9 to 12, 2017 – San Francisco (CA, USA).
  • Invest Securities Biomed Event, held on January 26, 2017 – Salons Hoche, Paris (France).

Please contact BIOCORP at investisseurs@biocorp.fr to arrange a meeting at any of these events.

see the press release

14 Dec 2016

EVENT – Pharmapack 2017 Feb 1,2 in Paris

BIOCORP will be exhibiting at 2017 edition of Pharmapack Europe 1st & 2nd February. Come visit us at booth H8! BIOCORP will display its innovations in the field of connected devices and pharmaceutical devices, and present its manufacturing activities (injection molding, assembly, packaging). Eric Dessertenne, Chief Operating Officer, will give a presentation at The Conference Session […]

BIOCORP will be exhibiting at 2017 edition of Pharmapack Europe 1st & 2nd February. Come visit us at booth H8!

BIOCORP will display its innovations in the field of connected devices and pharmaceutical devices, and present its manufacturing activities (injection molding, assembly, packaging).

Eric Dessertenne, Chief Operating Officer, will give a presentation at The Conference Session 2 on “Patient adherence: new challenges, new opportunities”, Wednesday 1st at 2.40 PM. He will explain how connected devices can not only monitor treatment adherence but also guarantee better and safer treatment administration.

BIOCORP will also participate to the Innovation Gallery, introducing NEWGUARD, a new generation integrated passive safety device compatible with various sizes of stacked needles PFS. This innovative solution creates new benefits for pharmaceutical companies in terms of supply chain, TCO and packaging. NEWGUARD meets both the economic criteria and the end users’ protection requirements.
During 2 days, various members of BIOCORP’s staff will be available to answer your questions and discuss about your future projects, including:

  • Eric Dessertenne, Chief Operating Officer
  • Thierry Guillemaut, Head of production
  • Alain Marcoz, Head of software R&D
  • Daniel Aneas, Head of product R&D
  • Patrick Quero, Head of quality and regulatory affairs
29 Nov 2016

PRESS – “Leverage technology to overcome pulmonary…”

LEVERAGE TECHNOLOGY TO OVERCOME PULMONARY DRUG DELIVERY CHALLENGES Here, Jean Vuillecard, Innovation & Product Manager, and Eric Dessertenne, Head of Business Development, define the limitations of traditional strategies to train, educate and track patient adherence with inhaled therapeutics and show how connectivity and other add-on digital technology can provide the support with these strategies that […]

LEVERAGE TECHNOLOGY TO OVERCOME PULMONARY DRUG DELIVERY CHALLENGES

Here, Jean Vuillecard, Innovation & Product Manager, and Eric Dessertenne, Head of Business Development, define the limitations of traditional strategies to train, educate and track patient adherence with inhaled therapeutics and show how connectivity and other add-on digital technology can provide the support with these strategies that healthcare providers require.

 

Pulmonary and nasal delivery

Read this article

(ONdrugDelivery Magazine, issue 72, “Pulmonary & Nasal Delivery”, on November the 29th 2016)

13 Oct 2016

PRODUCT LAUNCH – “Inspair, a smart sensor for inhalers”

The smart sensor to convert inhalers into connected devices to help patients with Asthma or Chronic Obstructive Pulmonary Diseases (COPD) ISSOIRE, France, October 6th, 2016 – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, today announces the launch of […]

The smart sensor to convert inhalers into connected devices to help patients with Asthma or Chronic Obstructive Pulmonary Diseases (COPD)

ISSOIRE, France, October 6th, 2016 – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, today announces the launch of Inspair, the smart sensor which converts inhalers into connected devices to help patients with Asthma or COPD.

“Biocorp’s objective is to develop innovative solutions in order to improve treatment compliance by patients suffering from chronic diseases. Significant applications have been developed in diabetology, endocrinology and neurology with the Datapen and Easylog devices, and our new sensor Inspair also positions us in the area of chronic lung diseases which affect an increasing number of people in need of new solutions to improve compliance”, said Jacques Gardette, Biocorp’s Founder and CEO

Asthma is a chronic disease which affects the respiratory tracts: it is characterized by an inflammation and irritation of the bronchial tubes which overreact to various triggers, and causes attacks with typical identifiable symptoms: difficulty in breathing, shortness of breath, dry cough or wheezing.
Asthma is a disease lived by 4 million people in France and 334 million in the world1, and which can rapidly affect the patients’ daily lives if it is not carefully controlled. The compliance and monitoring of the disease are all the more necessary in that a poor management of asthma can rapidly lead to severe asthma responsible for more than 500,000 emergency hospitalization and 1,000 to 1,500 deaths every year in France2. The French health insurance estimates that nearly six in ten people with asthma have inadequate control of their disease and treatment3.
COPD is a chronic lung disease which develops slowly and is characterized by an airway obstruction. It is different from Asthma and usually affects older people suffering from prolonged intoxication, mostly because of smoking (90%). COPD affects about 3 million people in France, and is responsible for more deaths than HIV or Influenza4. A fastidious treatment follow-up with inhaler and/or bronchodilator medication is thus required to reduce symptoms and improve the patient’s quality of life.

Inspair brings an innovative and effective response to the needs of these two pathologies: it acts directly on the treatment compliance and also strengthens the connection between the patient and the medical staff who can provide a real-time therapeutic follow-up. Inspair is a smart sensor capable of converting any pressurized metered dose inhaler into a connected device: it is then able to record data related to the inhalations and to assure an optimal management of the treatment (mastering of the inhalation technique). Equipped with miniaturized sensors and electronic card, Inspair fits on most MDI mouthpieces on the market using specific adaptors. The system automatically records data related to daily inhalations, ensures the right preparation of the canister (shake before usage), assesses the coordination of actuation with inhalation (“hand-mouth” coordination) and also provides with useful guidance throughout the inhalation steps.
Inspair acts on the key levers of the integrated therapeutic education which lowers hospital admissions and calls to emergency services, reduces the frequency of the attacks and other symptoms, and improves the patient’s daily comfort. More than a simple tool for treatment, Biocorp’s connected device becomes an integral part of it.
Still following its Intellectual Property strategy, providing the company with a key competitive advantage, Biocorp has deposited a series of international patents that ensure its full ownership, proof of anteriority and exclusive rights over the exploitation of Inspair.

27 Sep 2016

PARTNERSHIP – “Biocorp & Aguettant improving Parkinson’s disease care”

– This collaboration is part of the project “Health innovation for Auvergne-Rhône-Alpes” launched by the Auvergne-Rhône-Alpes region, the Regional Health Agency for Rhône-Alpes (ARS) and Bpifrance. In line with its development in e-health, BIOCORP extends its expertise to a new therapeutic indication: Parkinson’s disease.  Civil Hospices of Lyon (HCL) will bring their health care […]

– This collaboration is part of the project “Health innovation for Auvergne-Rhône-Alpes” launched by the Auvergne-Rhône-Alpes region, the Regional Health Agency for Rhône-Alpes (ARS) and Bpifrance. In line with its development in e-health, BIOCORP extends its expertise to a new therapeutic indication: Parkinson’s disease.  Civil Hospices of Lyon (HCL) will bring their health care expertise at different steps of the project deployment

ISSOIRE, France, September 27th, 2016 – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announces today the launch of APOKONNECT in partnership with Aguettant, laboratory specialized in the development, manufacturing and commercialization of essential medicines for hospitals. The APOKONNECT project selected by the Regional Health Agency (ARS), the Auvergne Rhône-Alpes region and Bpifrance, will combine the expertise of BIOCORP and Aguettant to improve the medical care and follow-up of patients suffering from Parkinson’s disease.

The Parkinson’s disease is a chronic neurodegenerative disease with very disabling motor symptoms, which affects around 200,000 people in France (25,000 new cases diagnosed each year1). Its therapeutic care is complex and requires high intensity care, especially in the case of motor fluctuations2 and demands a regular patient monitoring. The innovative APOKONNECT project will rely both on APOKINON®, an apomorphine self-injection pen developed by Aguettant, and on Easylog, the connected device developed by Biocorp. By connecting patients to healthcare professionals involved in the treatment, it will enable improvements of the patient’s medical care and ease the follow-up of the ambulatory treatment by apomorphine.

By gathering data related to patients’ treatment and symptoms on a tablet computer or smartphone via a secured app, this innovative treatment will not only help improve the treatment compliance and patients’ life, but will also increase their autonomy and lead to the development of “homecare” while staying connected to healthcare professional in real-time.

The study, carried out within the framework of the APOKONNECT project, will run for 19 months and include the system integration, different studies to assess the daily use and the preparation of the deployment. The tests, firstly undertaken at a regional level, will then be deployed on a larger scale. Financed by the Regional intervention fund of the Auvergne-Rhône-Alpes region, the Innovation Fund of Rhône-Alpes, namely the Social Innovation Funds, and Bpifrance’s financial apparatus, the project will widely contribute to the industrial and economic development of the Auvergne-Rhône-Alpes region and will help create employment. All the stakeholders of the project as well as their R&D and industrial activities are based in this region.

“Biocorp’s developments, namely in the e-health field, have always been driven by one major stake: improve the healthcare of patients suffering from chronic diseases. We wish to bring efficient and durable systems dedicated to the improvement of patients’ daily life and which contribute to the enhancement of the healthcare and medical support. The Parkinson’s disease, which is a new therapeutic indication covered by Biocorp, opens new business perspectives and confirms our strategic development. We are pleased to collaborate with Aguettant and all the partners involved in this promising project”, commented Jacques Gardette, Biocorps’ CEO and Co-founder.

“Aguettant has been a key player in the treatment of Parkinson’s disease for many years. Our leading product APOKINON® and collaboration with French neurologists have driven improvements in the healthcare of this pathology. The APOKONNECT project fits into this framework and will combine Aguettant’ and Biocorp’s potential for innovation, the expertise of our academic teams involved in the medical progress and the globalization of our therapeutic offer”, declared Eric Rougemond, Aguettant Laboratory’s CEO. 

For more information on the «Health innovation for Auvergne-Rhône-Alpes” project, please visit: http://www.ars.auvergne-rhone-alpes.sante.fr/Projets-innovants-en-sante.174787.0.html (French only)

 

 

20 Jan 2015

EVENT – “Drug delivery partnerships 2015”

BIOCORP will be in Boca Raton, Florida, to attend the 19th annual « Drug delivery partnerships » event from the 28th to the 30th of January 2015.

BIOCORP will be in Boca Raton, Florida, to attend the 19th annual « Drug delivery partnerships » event from the 28th to the 30th of January 2015.

Eric Dessertenne, Head of Business Development and Commercial Operations at BIOCORP, will attend the meeting to discuss the latest trends in drug delivery and the future positioning of our products. We would be glad to exchange with you on these topics and you can reach Eric Dessertenne by phone (+33 6 08 02 14 51) or by mail at edessertenne@www.biocorp.fr to schedule a meeting.

04 Jan 2015

Pharmapack Europe 2015

BIOCORP will exhibit both its smart and traditional devices. Eric Dessertenne, Head of Commercial Operations and Business Development, and Antoine Aneas, Head of Research & Development, will attend the event to discuss our latest innnovations.

BIOCORP will attend the 2015 edition of Pharmapack Europe the 11th and 12th February with the booth number 1029

pharmapack-logo-2015-with-date_xs

 

 

 

BIOCORP will exhibit both its smart and traditional devices. Eric Dessertenne, Head of Commercial Operations and Business Development, and Antoine Aneas, Head of Research & Development, will attend the event to discuss our latest innovations.

Thierry Guillemaut, Head of Production, will also attend to advertise our manufacturing unit. Indeed, BIOCORP also develops and produces tailor-made products for companies in the pharmaceutical industry thanks to state-of-the art industrial equipment and a strong knowledge in plastics engineering. BIOCORP produces in a clean-room environment and sterelised packages.

Eric Dessertenne will be presenting the role of connected drug delivery devices on Wednesday 11th February at 2.30 PM at the Learning Lab.

Connected drug delivery systems: increase patient compliance and enable comprehensive, coordinated treatments

He will cover the following topics:

  • BIOCORP, a pioneer in connected drug delivery systems : reusable injection pens, treatment management add-ons…
  • Patient-focused solutions : increase compliance, security, allow monitoring by physicians and information sharing with other patients
  • Integrated solutions : product conception and certification, software development, database management
  • Available for a large number of chronic disease delivered by injection : Diabetes, Multiple Sclerosis, Growth Hormone Treatment…
  • On the edge of new Mhealth trends : software compatible with patient community platform, Apple Health Kit…

You can register for the exhibition for free to attend our presentation.